← Back to 25C-NBOMe

25C-NBOMe Stats & Data

Psychedelic Research-chemical

25c 2c-nbome Cimbi-82 2c-c-nbome Nbome-2c-c

NPS DataHub

MW335.83

FormulaC18H22ClNO3

CAS1227608-02-7

IUPAC2-(4-chloro-2,5-dimethoxyphenyl)-~{N}-[(2-methoxyphenyl)methyl]ethanamine

SMILESCOc1ccccc1CNCCc1cc(OC)c(Cl)cc1OC

InChIKeyFJFPOGCVVLUYAQ-UHFFFAOYSA-N

Phenethylamines; 2020/1. Von 2-Phenethylamin abgeleitete Verbindungen; 2021/1. Von 2-Phenethylamin abgeleitete Verbindungen; 2022/1. Von 2-Phenethylamin abgeleitete Verbindungen

Chemical Class Phenethylamine

Psychoactive Class Psychedelic

History & Culture

25C-NBOMe was discovered in 2003 by Ralf Heim at the Free University of Berlin. The compound was subsequently investigated by a research team at Purdue University led by David Nichols, and was first formally described in the scientific literature by Anders Ettrup and colleagues in 2010. Research interest in 25C-NBOMe has centered on its potential applications in neuroimaging. Scientists have studied its carbon-11 radiolabelled form as a ligand for mapping the distribution of serotonin 5-HT2A receptors in the brain using positron emission tomography (PET). The compound had virtually no history of recreational human use prior to 2010, when it first emerged on the online research chemical market. Its exceptional potency—approximately sixteen times that of its parent compound 2C-C—allows effective doses to fit onto blotter paper, similar to LSD. This characteristic has led to instances where 25C-NBOMe has been found on blotter mimics sold as LSD, contributing to safety concerns and prompting regulatory responses across numerous jurisdictions beginning in 2011.

Subjective Effect Notes

physical: The physical effects of 25C-NBOMe can be broken down into several components which progressively intensify proportional to dosage.

cognitive: The cognitive effects of 25C-NBOMe are described by many as remarkably light and underwhelming in comparison to more traditional psychedelics. It is not uncommon for people to report feeling that their thought stream has maintained general normality in its specific style throughout low to moderate dosages. At high dosages, however, mild to overwhelming cognitive alterations become present; this dosage seems to be lower in proportion to physical effects when compared to 25I-NBOMe.

Effect Profile

Curated + 136 Reports

Psychedelic 8.8

Strong visuals, headspace, auditory effects, and body load

Visual Intensity×3

10103.0

Headspace Depth×3

10102.2

Auditory Effects×1

10102.2

Body Load / Somatic Effects×1

108.85.2

Catalog Erowid BlueLight

Based on reports from:

Effect Index An Interesting Night — nervewing Bluelight Big & Dandy Thread Erowid Experience Reports PsychonautWiki 25C-NBOMe

Duration Timeline

Bluelight

Onset Comeup Peak Offset After Effects

Sublingual

0-12 minutes

30 minutes - 1.5 hours

4-6 hours

1-4 hours

1-24 hours

Total: 8-10 hours

Insufflated

45-90 minutes hours

1-24 hours

Total: 5-8 hours

Community Effects

TripSit

Positive

visual enhancement creativity

Negative

nausea vomiting body load

Tolerance & Pharmacokinetics

drugs.wiki

Tolerance Decay

Full tolerance 1h Half tolerance 10d Baseline ~14d

Cross-Tolerances

LSD

60% ●○○

Psilocybin

65% ●○○

Psilocin

65% ●○○

Mescaline

85% ●○○

DMT

65% ●○○

5-MeO-DMT

65% ●○○

2C-B

85% ●○○

2C-E

85% ●○○

Experience Report Analysis

Erowid BlueLight

113 Reports

2010–2015 Date Range

107 With Age Data

35 Effects Detected

Demographics

Gender Distribution

Age Distribution

Reports Over Time

Effect Analysis

Erowid + Bluelight

Effects aggregated from 136 experience reports (113 Erowid + 23 Bluelight)

136 Reports

106 Effects Detected

39 Positive

46 Adverse

21 Neutral

Effect Sentiment Distribution

Confidence Distribution

Positive Effects 39

Music Enhancement 59.3% 70%

Color Enhancement 57.3% 86%

Euphoria 53.0% 88%

Stimulation 39.7% 82%

Empathy 32.4% 85%

Surface Breathing 30.4% 82%

Focus Enhancement 30.1% 78%

Introspection 27.9% 80%

Tactile Enhancement 27.2% 81%

Body High 22.8% 85%

Visual Trails 21.7% 86%

Geometric Imagery 17.4% 84%

Contentment 17.4% 79%

Tingling 17.4% 86%

Patterning 17.4% 89%

Clarity 13.0% 82%

Pain Relief 12.4% 70%

Visual Sharpening 8.7% 82%

Visual Clarity 8.7% 82%

Auditory-Visual Synesthesia 8.7% 78%

Adverse Effects 46

Anxiety 58.1% 87%

Confusion 31.6% 82%

Body Load 30.4% 80%

Fear 26.1% 90%

Thought Disorganization 26.1% 81%

Nausea 25.0% 85%

Tremor 21.7% 77%

Body Temperature Change 21.7% 81%

Muscle Tension 13.9% 85%

Thought Loops 13.2% 90%

Insomnia 13.0% 83%

Paranoia 13.0% 87%

Panic 13.0% 95%

Headache 11.8% 82%

Increased Heart Rate 11.5% 70%

Memory Suppression 11.0% 90%

Pupil Dilation 11.0% 88%

Sweating 9.5% 75%

Jaw Clenching 8.8% 82%

Paranoid Ideation 8.7% 90%

Dose-Response Correlation

How effect frequency changes across dose levels

View data table

Effect	Common (n=25)	Strong (n=13)
Visual Distortions	100.0%	92.3%
Music Enhancement	60.0%	76.9%
Color Enhancement	76.0%	69.2%
Euphoria	72.0%	61.5%
Anxiety	68.0%	61.5%
Introspection	36.0%	53.8%
Dissociation	36.0%	46.2%
Empathy	32.0%	46.2%
Body High	32.0%	46.2%
Sedation	24.0%	46.2%
Confusion	40.0%	23.1%
Nausea	40.0%	23.1%
Stimulation	32.0%	38.5%
Focus Enhancement	32.0%	38.5%
Tactile Enhancement	24.0%	38.5%

Subjective Effect Ontology

Experience Reports

Structured effect tags extracted from 136 Erowid & Bluelight experience reports using a controlled vocabulary of 220+ canonical effects across 15 domains.

Visual

visual distortions 108 79.4%

1 unique effects extracted · Derived from Erowid & Bluelight reports

Dose–Effect Mapping

Experience Reports

How reported effects shift across dose tiers, based on 113 experience reports.

Limited tier coverage — most reports fall within the Common / Strong range. Effects at other dose levels may not be represented.

Sublingual dose range: 300.0–600.0 µg (median 500.0 µg)

Effect	Common (n=25)	Strong (n=13)
visual distortions	100%	92%	→
music enhancement	60%	77%	↑
color enhancement	76%	69%	→
euphoria	72%	62%	→
anxiety	68%	62%	→
introspection	36%	54%	↑
dissociation	36%	46%	↑
empathy	32%	46%	↑
body high	32%	46%	↑
sedation	24%	46%	↑
confusion	40%	23%	↓
nausea	40%	23%	↓
stimulation	32%	38%	↑
focus enhancement	32%	38%	↑
tactile enhancement	24%	38%	↑
closed-eye visuals	24%	38%	↑
pain relief	12%	38%	↑
auditory effects	32%	23%	↓
open-eye visuals	32%	15%	↓
sweating	—	31%	→

Showing top 20 of 33 effects

Risk Escalation

Sentiment Analysis

Average frequency of positive vs adverse effects across dose tiers

Common n=25

11 positive 37.8% 10 adverse 24.4%

Strong n=13

10 positive 50.8% 12 adverse 23.7%

View effect breakdown

Adverse Effects

Effect	Common (n=25)	Strong (n=13)	Change
Anxiety	68%	62%	-9%
Confusion	40%	23%	-42%
Nausea	40%	23%	-42%
Sweating	—	31%	0%
Headache	20%	23%	+15%
Thought Loops	16%	23%	+44%
Pupil Dilation	12%	23%	+92%
Increased Heart Rate	16%	—	0%
Muscle Tension	16%	15%	-3%
Memory Suppression	8%	15%	+92%
Jaw Clenching	8%	15%	+92%
Motor Impairment	—	15%	0%
Psychosis	—	15%	0%

Positive Effects

Effect	Common (n=25)	Strong (n=13)	Change
Music Enhancement	60%	77%	+28%
Color Enhancement	76%	69%	-8%
Euphoria	72%	62%	-14%
Introspection	36%	54%	+49%
Empathy	32%	46%	+44%
Body High	32%	46%	+44%
Stimulation	32%	38%	+20%
Focus Enhancement	32%	38%	+20%
Tactile Enhancement	24%	38%	+60%
Pain Relief	12%	38%	+220%
Creativity Enhancement	8%	—	0%

Dosage Distribution

Dose distribution from experience reports

Insufflated

Median: 600.0 µg IQR: 400.0–1300.0 µg n=15

Sublingual

Median: 500.0 µg IQR: 300.0–600.0 µg n=15

Real-World Dose Distribution

62K Doses

From 125 individual dose entries

Sublingual (n=48)

Median: 0.51mg 25th: 0.38mg 75th: 0.93mg 90th: 1.0mg

mg/kg median: 0.006 mg/kg 75th: 0.012

Insufflated (n=21)

Median: 0.4mg 25th: 0.25mg 75th: 0.6mg 90th: 1.3mg

mg/kg median: 0.006 mg/kg 75th: 0.012

Oral (n=10)

Median: 0.9mg 25th: 0.62mg 75th: 1.38mg 90th: 1.55mg

mg/kg median: 0.016 mg/kg 75th: 0.024

Common Combinations

Most co-occurring substances in experience reports

Form / Preparation

Most common forms and preparations reported

Body-Weight Dosing

Dose relative to body weight from reports with weight data

Oral

Median: 0.024 mg/kg IQR: 0.011–0.034 mg/kg n=6

Insufflated

Median: 0.007 mg/kg IQR: 0.005–0.014 mg/kg n=15

Sublingual

Median: 0.006 mg/kg IQR: 0.004–0.007 mg/kg n=14

Unknown

Median: 0.01 mg/kg IQR: 0.006–0.014 mg/kg n=17

Redose Patterns

Redosing behavior across 100 reports

14.0% Redosed

1.2 Avg Doses

180m Median Interval

Read full reports on Erowid →

Legal Status

Country	Status	Notes
Austria	Illegal (SMG)	Prohibited since June 26, 2019 under the Suchtmittelgesetz (SMG). Possession, production, and sale are illegal.
Brazil	Controlled	Listed on Portaria SVS/MS nº 344 as of February 18, 2014. The entire NBOMe series became controlled at this time, including 25I-, 25C-, 25D-, 25B-, 25E-, 25N-, 25P-, 25T2-, 25T7-, and 25H-NBOMe.
Canada	Schedule III (CDSA)	Controlled as of October 31, 2016 as a derivative of 2,5-dimethoxyphenethylamine under the Controlled Drugs and Substances Act.
China	Controlled	Classified as a controlled substance since October 2015.
Czech Republic	Banned	Prohibited under national controlled substances legislation.
Germany	Anlage I BtMG	Listed in Anlage I of the Betäubungsmittelgesetz (Narcotics Act) since December 13, 2014. Manufacturing, possession, import, export, purchase, sale, procurement, and dispensing without a license are prohibited.
Israel	Controlled	The NBOMe series became controlled in May 2013.
Italy	Schedule I	Classified as a Schedule I controlled substance. Possession, distribution, and manufacture are illegal.
Japan	Narcotic	Designated as a narcotic drug effective November 1, 2015.
Latvia	Schedule I	Classified as a Schedule I controlled substance.
New Zealand	Class C analogue	Considered substantially similar in chemical structure to the controlled hallucinogen DOB and therefore treated as a Class C controlled drug analogue. Withdrawn from sale in early 2012 following a statement by Associate Health Minister Peter Dunne.
Russia	Controlled	The entire NBOMe series became controlled in October 2011, making Russia the first country to regulate this class of substances.
Sweden	Schedule I	Added to Schedule I (substances without medical use) as of August 1, 2013, published in Medical Products Agency regulation LVFS 2013:15.
Switzerland	Controlled (Verzeichnis D)	Specifically named as a controlled substance under Verzeichnis D of Swiss narcotics legislation.
Turkey	Illegal	Classified as a controlled drug. Possession, production, supply, and import are prohibited.
United Kingdom	Class A	Controlled as a Class A substance since June 2014 under the N-benzylphenethylamine catch-all clause in the Misuse of Drugs Act 1971. Previously subject to a temporary class drug order from June 10, 2013.
United States	Schedule I	Emergency scheduled by the DEA on November 15, 2013, along with 25B-NBOMe and 25I-NBOMe under the Controlled Substances Act. The temporary scheduling was extended in November 2015. Several states including Arkansas, Georgia, and Louisiana added it to their Schedule I lists prior to federal action. Scheduling also makes other NBOMe compounds probable Controlled Substance Analogues when intended for human consumption.

← Back to 25C-NBOMe